Europe Tissue Diagnostics Market Research Report - Segmented By Product Type, Application, End User, Disease & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2024 to 2029)

Updated On: January, 2024
ID: 4091
Pages: 130

Europe Tissue Diagnostics Market Size (2023 to 2028)

According to the research report, the Europe Tissue Diagnostics Market size is estimated to be worth USD 1.66 billion by 2028 and USD 1.20 billion in 2023, growing at a CAGR of 6.70% during the forecast period.

The rising prevalence of cancer, the improving infrastructure for cancer detection, the recommendation of cancer screening, the availability of reimbursements, and rising healthcare expenditures are all driving this European tissue diagnostics market forward. Increased use of automated tissue diagnostics to detect illnesses such as cancer, increased healthcare spending, and growth in the cancer population are some of the reasons driving the market forward throughout the forecast period. Furthermore, the rise in the geriatric population, which is more susceptible to immunological diseases, and the increased usage of customized medications to treat different chronic conditions, such as cancer, fuel the diagnostics market in Europe. Tissue diagnostics captures the disease insights and factors that influence patient outcomes. Tissues, in general, provide for individualized diagnosis and therapy. The majority of samples are made up of tissue fragments acquired through various procedures. Small biopsies and big specimens extracted during surgery are instances.

Increased tissue diagnostics in hospitals for cancer monitoring, diagnosis, and management at various stages, including breast cancer, prostate cancer, and other cancers. Because these methods capture the biological environment of malignancies, tissue diagnostics remains one of the gold standards for cancer diagnosis. With the rise in cancer cases, the market for tissue diagnostics has seen a surge in demand, with promising development prospects in the near future. For the development of innovative tests, personalized medicine heavily relies on the utilization of human tissue. The use of tissue diagnostics is driven by an increase in the deployment of sequencing technologies and healthcare IT systems in the clinical workflow, which has greatly extended customized medicine. In addition, the growing disease burden is driving the demand for effective and rapid treatment alternatives, which is likely to drive European tissue diagnostics market growth during the forecast period.

The rising cost of tissue diagnostics equipment and the rising cost of treatment is expected to hamper the growth rate of the European tissue diagnostics market. In addition, government regulations and unfavorable reimbursement policies are expected to limit the diagnostics market's growth in Europe.

This research report on the European Tissue Diagnostics Market has been segmented and sub-segmented into the following categories:

By Product Type: 

  • Instruments
  • Consumables

By Application: 

  • Immunohistochemistry
  • Hematoxylin and Eosin
  • In Situ Hybridization

By End User: 

  • Contract Research Organizations
  • Hospitals
  • Diagnostic Laboratories
  • Research Organizations
  • Biotechnology Companies

By Disease: 

  • Lung Cancer
  • Lymphoma
  • Pancreatic Cancer
  • Breast Cancer
  • Others

By Country: 

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, The tissue diagnostic market in the European area is growing due to increased public programs to reduce cancer risk and a rise in cancer demand. In addition, due to an increase in the prevalence of infectious illnesses, immunodiagnostics in infectious disease diagnosis has increased. Other factors that contribute to the growth of the German tissue diagnostics market include the increased usage of fast tests such as continuous glucose monitoring and flash glucose monitoring. The easy availability of advanced technologies, government initiatives for cancer patient screening, favorable reimbursement scenarios for pathology diagnostic tests, rising healthcare expenditures, and high-quality infrastructure for hospitals and clinical laboratories in this region are the major factors driving the tissue diagnostic market's growth in Europe.


A few of the promising companies operating in the Europe Tissue diagnostics Market profiled in this report are F. Hoffmann-La Roche AG, Sigma-Aldrich Co. LLC, Abbott Laboratories, Agilent Technologies, BioGenex, Danaher Corporation, Cell Signaling Technology, and Ventana Medical Systems.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample